(PALO ALTO, Calif.) – CellBio Scientific, a leading drug discovery and clinical solutions provider, announced the acquisition of Acepix Biosciences, a California-based company known for its innovative histopathology services and cellular imaging products. This acquisition marks a significant step in CellBio Scientific’s strategic growth plan, aimed at offering a broader and more integrated portfolio of products and services to the life sciences research community.

Acepix Biosciences has built a reputation for excellence in histology, immunohistochemistry (IHC), and high-resolution microscopy imaging, serving both academic and industry clients. The integration of Acepix’s expertise and service platform into CellBio’s existing product line will empower researchers with a more comprehensive toolkit for studying disease mechanisms, developing therapeutics, and advancing precision medicine.

“This acquisition is about doing the best science for our customers,” said Charles Miller, Founding CEO of CellBio Scientific. “Acepix brings deep knowledge in histopathology and tissue-based imaging that perfectly complements our corporate strength. Together, we’ll be able to offer end-to-end research support — from tissue to data — that accelerates scientific discovery and innovation.” The acquisition also positions CellBio to meet growing demands in translational research and drug development, where high-quality imaging and pathology support are increasingly critical.

“This is an exciting time for our team,” Miller added. “We share a common mission to empower scientists with the tools and insights they need to push boundaries. By combining forces, we’re delivering on that mission in a bigger, bolder way.”

The companies will begin integration immediately, with Acepix’s operations continuing under the CellBio Scientific brand. Clients can expect uninterrupted service and enhanced access to a wider array of research solutions in the coming months.